Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and... see more

TSXV:RHT.H - Post Discussion

Reliq Health Technologies Inc > Another New Contract
View:
Post by 600Volt on Feb 24, 2021 3:43am

Another New Contract

HAMILTON, Ontario, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a new contract with a US Nephrology practice to use Reliq’s proprietary iUGO Care platform to monitor Chronic Kidney Disease (CKD) patients.

“It is a testament to the flexibility of our platform that it can be used to manage so many different complex chronic conditions,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “We are pleased to be working with our newest client, a Nephrology Practice in Texas, to monitor Chronic Kidney Disease patients and help improve their health outcomes. Over 36 Million Americans have CKD and the majority of these patients also have either diabetes and/or hypertension, the two primary risk factors for developing Chronic Kidney Disease. Using our highly scalable iUGO Care platform, Nephrologists can help monitor medication compliance and manage patients’ co-morbidities like diabetes and high blood pressure, helping to reduce or prevent further damage to the kidneys that could lead to End Stage Renal Disease (ESRD) and the need for costly and disruptive interventions like dialysis or a kidney transplant. We will begin onboarding patients next week, and expect to have at least 5,000 kidney disease patients on the platform by the end of this calendar year, at an average revenue of $65 USD/patient/month.”

Reliq Health

 

Comment by Canadian_101 on Feb 24, 2021 5:56am
Well i was not to far off, thought another contract announcement would be released before earnings reporting day....good to see that some concrete numbers were given which will increase revenue depending on actual onboarding numbers.
Comment by GustheGreek on Feb 24, 2021 6:21am
Yes another one, and the boost from the wall street reporter should pop this thing today. Looking for at least 90 cents by day's end.
Comment by Calgary1111 on Feb 24, 2021 5:59pm
Just revisted last weeks highs before pulling back. Not to sure what its going to take to get this thing to a buck again and keep it there. Its been a nice 12 weeks for us reliq shareholders.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities